Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00924352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective for the Phase I portion of the study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) and for the Phase II portion of the study is to evaluate progression free survival (PFS). Secondary objectives are response rate, clinical benefit rate, and overall toxicity.
Study identification
- NCT ID
- NCT00924352
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Oct 2013 (Actual)
- Completion
- Oct 2013 (Actual)
- Last update posted
- Oct 13, 2014
2009 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hematology Oncology PC | Stamford | Connecticut | 06902 | — |
| Central Georgia Cancer Care | Macon | Georgia | 31201 | — |
| Northwest Georgia Oncology Centers | Marietta | Georgia | 30060 | — |
| North Shore Cancer Research | Skokie | Illinois | 60076 | — |
| Hematology Oncology Associates of the Quad Cities | Bettendorf | Iowa | 52722 | — |
| Baystate Medical Center | Springfield | Massachusetts | 01107 | — |
| Hematology Oncology Centers of the Northern Rockies | Billings | Montana | 59101 | — |
| Oncology Hematology Specialists, P.A. | Denville | New Jersey | 07834 | — |
| The Moses H. Cone Regional Cancer Center | Greensboro | North Carolina | 27403 | — |
| North Coast Cancer Care | Sandusky | Ohio | 44870 | — |
| Pennsylvania Oncology Hematology Associates | Philadelphia | Pennsylvania | 19106 | — |
| University of Tennessee Cancer Institute | Memphis | Tennessee | 38104 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00924352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2014 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00924352 live on ClinicalTrials.gov.